Twenty-one studies were considered, including three studies based on liver histology, showing that GLP-1 RAs and SGLT2 inhibitors decreased hepatic steatosis and steatohepatitis in NAFLD patients, while DPP-4 inhibitor therapy was not effective for patients with hepatic steatosis [67]. The gene discussed is DPP4; the disease is metabolic dysfunction-associated steatotic liver disease.